Roche Holding AG | Income Statement

Fiscal year is January-December. All values CHF Millions.
2013
2014
2015
2016
2017
Sales/Revenue
46,780
47,462
48,145
50,576
53,299
Cost of Goods Sold (COGS) incl. D&A
12,924
12,950
14,208
14,982
15,851
Gross Income
33,856
34,512
33,937
35,594
37,448
SG&A Expense
18,541
19,322
19,835
20,403
22,071
EBIT
15,034
-
13,797
14,875
15,066
Unusual Expense
696
3,620
2,715
3,027
4,620
Non Operating Income/Expense
1,403
2,411
1,766
1,844
2,372
Interest Expense
1,085
946
885
707
598
Pretax Income
14,683
12,515
11,987
13,007
12,250
Income Tax
3,304
2,980
2,931
3,274
3,423
Equity in Affiliates
6
-
-
-
2
Consolidated Net Income
11,373
9,535
9,056
9,733
8,825
Net Income
11,164
9,332
8,863
9,576
8,633
Net Income After Extraordinaries
11,164
9,332
8,863
9,576
8,633
Net Income Available to Common
11,164
9,332
8,863
9,576
8,633
EPS (Basic)
13.16
10.99
10.41
11.24
10.12
Basic Shares Outstanding
848
849
851
852
853
EPS (Diluted)
12.94
10.81
10.28
11.13
10.04
Diluted Shares Outstanding
863
863
862
860
860
EBITDA
17,415
17,278
17,449
18,826
18,957
Other Operating Expense
281
554
305
316
311
Non-Operating Interest Income
27
34
24
22
30
Minority Interest Expense
209
203
193
157
192

About Roche Holding

View Profile
Address
Grenzacherstrasse 124
Basel Basel-Stadt (Basle Town) 4070
Switzerland
Employees -
Website http://www.roche.com
Updated 09/14/2018
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.